AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04842188 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: L-PRF
Description: surgical open flap debridement followed by L-PRF alone
Study NCT04034251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel (intraperitoneal (IP) and intravenous (IV), Day 1 of each 3-week cycle: Paclitaxel IP - Intraperitoneal paclitaxel (60 mg/m\^2) will be diluted in 500 mL of 0.9% normal saline (NS), to be infused as rapidly as tolerated once per 3-week cycle on Day 1. Paclitaxel IV - Intravenous paclitaxel (80 mg/m\^2) will be administered concomitantly over 3 hours, diluted in 100 to 250 ml of 0.9% NS once per 3-week cycle on Day 1.
Study NCT04034251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Day 1-15 of each 3-week cycle: oral capecitabine (825 mg/m\^2) to be taken twice a day starting the evening of Day 1 of each cycle until the morning of Day 15, followed by a 7-day rest period during each 3-week cycle.
Study NCT04034251 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BardPort Titanium Implanted Port with Peritoneal Catheter
Description: After peritoneal chemo infusion port is placed (Days 1-3, as dictated by clinical status), patients will begin intraperitoneal paclitaxel and intravenous paclitaxel (Day 1) followed by oral capecitabine on the evening of Day 1 to the morning of Day 15.
Study NCT04506905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8189
Description: MK-8189, oral, 4 mg and/or 12 mg tablets for a total daily dose of 8, 16 or 24 mg QD according to randomization
Study NCT01636830 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Toothbrush type
Description: Evaluate the use of toothbrushes with bristles soft and medium
Study NCT02919397 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wearable technology
Description: Buddi wearable technology will record activity levels, participants will access activity data through smartphone application
Study NCT02919397 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable technology
Description: Buddi wearable technology will record activity levels, participants will access activity data through smartphone application
Study NCT02919397 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Prevention Programme educational material
Description: Educational material accessed through smartphone application
Study NCT04506905 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablets of dose-matched placebo to MK-8189 according to randomization
Study NCT04768127 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: early aftercare
Description: This group begins the aftercare program immediately after their bariatric surgery.
Study NCT04768127 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mid-term to late aftercare
Description: This group begins the aftercare program 18 months post surgery.
Study NCT06090643 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive CRC screening usual care
Study NCT06090643 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Consultation
Description: Receive consultation with clinic staff
Study NCT06090643 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive education and training on CRC screening
Study NCT06090643 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Health Record Review
Description: Ancillary studies
Study NCT06090643 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies
Study NCT06090643 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal Immunochemical Test
Description: Receive FIT kit with culturally tailored instructions
Study NCT06090643 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback
Description: Receive feedback on CRC screening
Study NCT06090643 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education
Description: Receive CRC screening recommendations
Study NCT06090643 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Support Education Activity
Description: Utilize clinical decision support tool
Study NCT06090643 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Message-Based Navigation Intervention
Description: Receive text message reminders
Study NCT02344290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitavastatin
Description: One tablet (4 mg) taken once daily, orally with or without food
Study NCT02344290 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One tablet taken once daily, orally with or without food
Study NCT04245215 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ustekinumab
Description: re-induction and dose escalation form every 8 weeks to every 4 weeks only in arm 2
Study NCT04245215 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ustekinumab
Description: re-induction and dose escalation form every 8 weeks to every 4 weeks only in arm 2
Study NCT04542408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anticoagulation Agents (Edoxaban and/or high dose LMWH)
Description: In-hospital (ICU \& normal ward): weight-adapted LMWH, high dose/ therapeutic dose (according to respective SmPC) After discharge and in ambulatory patients: Edoxaban according to SmPC until
Study NCT04542408 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Low dose Low molecular weight heparin or Placebo
Description: In-hospital (ICU \& normal ward): LMWH, prophylactic dose as part of SOC After discharge and in ambulatory patients: Administration of oral pla-cebo according to the dosing rules for Edoxaban
Study NCT03082833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2014
Description: AZD2014 is a selective dual mTOR kinase inhibitor targeting both mTORC1 (rapamycin sensitive) and mTORC2 (rapamycin insensitive) complexes of mammalian Target Of Rapamycin (mTOR).
Study NCT01381952 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low dose DSA (75% reduction compared to normal dose) with novel X-ray imaging technology.
Description: Digital substraction angiography (DSA) with reduced dose settings (75% reduction expected) in combination with conventional X-ray imaging technology.
Study NCT01381952 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Normal dose DSA with conventional X-ray technology
Description: Digital substraction angiography (DSA) with normal dose settings in combination with conventional X-ray imaging technology.
Study NCT03671733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: The treatment of Liraglutide lasted three months,During the first week: 0.6mg per day, subcutaneous injection;During the second week: 1.2mg per day, subcutaneous injection; From third week onwards, 1.8mg per day, subcutaneous injection.
Study NCT01892111 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured exercise program.
Study NCT03671733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: 10mcg once a day for 4 weeks increased to 10mcg twice a day for 8 weeks.
Study NCT03671733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide Microspheres for Injection
Description: Exenatide 2 mg injection once weekly for 12 weeks.
Study NCT02919397 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Prevention Programme educational material
Description: Educational material accessed through smartphone application
Study NCT02919397 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational messaging
Description: Messages sent via smartphone application
Study NCT02643953 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentives
Description: 1) provision of incentives to encourage women to attend primary health care and use family planning, antenatal, delivery and postnatal services; 2) conditional cash transfers to promote uptake of services; 3) targeted community health education and advocacy activities; 4) community maternal audit/accountability activities, with community-led activities aimed at promoting utilization of services
Study NCT02643953 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community
Description: 1) outreach services by PHCs; 6) PHC strengthening including training of health providers; and 2) training and kitting of community health rangers who will be trained to follow up women at home to ensure that they do not default but that they continue to use PHC services until delivery.
Study NCT02768077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin(Circadin®)
Study NCT04451343 — intervention group
Intervention type: OTHER
Intervention: biographical interviews
Description: A sociologist trained in the sociology of cancer, to enable participants to talk about their experiences and clearly distinguish the experiences of each individual
Study NCT02768077 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01723514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erenumab
Description: Administered by subcutaneous injection once a month
Study NCT02289287 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Management group-intervention
Description: At enrollment eligible patients will be randomized to Intervention + Standard Care or Standard Care group. Within 3 weeks after enrollment all participants will undergo baseline assessment using a predefined set of scales and questionnaires (intervention group will additionally undergo a semi-structured interview). The group-intervention (SM program) will begin after enrollment of at least 4 participants to the intervention group, and within no longer than 5 weeks since enrollment. The intervention will include 12 weekly sessions, each session 2.5 hour long, and will be based on well-known SM interventions that were found effective for stroke patients in the U.S. Follow-up assessments will be done at 12 and 36 week to examine long term effectiveness.
Study NCT02289287 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: At enrollment eligible patients will be randomized to Intervention + Standard Care or Standard Care group. Within 3 weeks after enrollment all participants will undergo baseline assessment using a predefined set of scales and questionnaires (intervention group will additionally undergo a semi-structured interview). Standard care will include 'one-on-one' sessions in each paramedical discipline as given regularly in this setting (average of 15-20 sessions per patient). Follow-up assessments will be done at 12 and 36 week to examine long term effectiveness.
Study NCT02459184 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Income Security Health Promotion
Description: The ISHP will work to improve the income security of participants within this study. To that end, her activities include:~* Providing one-to-one case management support and ongoing follow-up to diverse low-income patients and families regarding their income security.~* Developing and implementing targeted information self-help sessions, such as; banking basics, income tax submissions, and social service forms, for the target population~* Developing and maintaining up-to-date detailed knowledge of financial issues and financial services affecting low-income people, and applying this knowledge in his/her work.~* Assisting individual low-income patients with income security-focused interventions, including access to tax benefits, applications for income security programs such as social assistance and seniors and child benefits, and navigation of disability support programs.
Study NCT02459184 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Income Security Health Promotion
Description: The ISHP will work to improve the income security of participants within this study. To that end, her activities include:~* Providing one-to-one case management support and ongoing follow-up to diverse low-income patients and families regarding their income security.~* Developing and implementing targeted information self-help sessions, such as; banking basics, income tax submissions, and social service forms, for the target population~* Developing and maintaining up-to-date detailed knowledge of financial issues and financial services affecting low-income people, and applying this knowledge in his/her work.~* Assisting individual low-income patients with income security-focused interventions, including access to tax benefits, applications for income security programs such as social assistance and seniors and child benefits, and navigation of disability support programs.
Study NCT01630408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Description: Paricalcitol oral capsules 1 mcg/day for 48 weeks
Study NCT01723514 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection once a month
Study NCT00989313 — intervention group
Intervention type: DRUG
Intervention: Lesion count
Description: Lesion count in area treated by study drug in a prior study. No drug will be applied during this long-term follow up study. Drug was applied during the primary study.
Study NCT01336387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: retinoid 9cUAB30
Description: Given PO
Study NCT01336387 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO
Study NCT01336387 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT01336387 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: pharmacological study
Description: Correlative studies
Study NCT01336387 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01336387 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01336387 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cancer prevention
Description: Disease prevention
Study NCT01336387 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: cancer prevention
Description: Disease prevention
Study NCT03779321 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Acceptability
Description: Food samples two formulations (low and high acceptability levels) of custard were used as experimental meals
Study NCT02234635 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diffractive multifocal IOLs group
Description: Diffractive IOLs are a type of multifocal (bifocal) IOL that are based on the Huygens-Fresnel principle. Specifically, a diffractive IOL has concentric rings in its posterior surface that form 2 primary focal points independent of pupil size. This optical behavior of the IOL can effectively restore far and near vision. However, it can also cause side effects, such as halos and glare and loss of contrast sensitivity.
Study NCT02234635 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Diffractive multifocal IOLs group
Description: Diffractive IOLs are a type of multifocal (bifocal) IOL that are based on the Huygens-Fresnel principle. Specifically, a diffractive IOL has concentric rings in its posterior surface that form 2 primary focal points independent of pupil size. This optical behavior of the IOL can effectively restore far and near vision. However, it can also cause side effects, such as halos and glare and loss of contrast sensitivity.
Study NCT02236702 — intervention group
Intervention type: OTHER
Intervention: Positron Emission Tomography (PET) imaging
Description: Positron Emission Tomography (PET) imaging
Study NCT00919009 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE (Transcatheter Arterial Chemoembolization )
Description: TACE will be performed according to National Cancer Center protocol:~Briefly, an arterial catheter was inserted into the femoral artery by the Seldinger method and placed in the hepatic artery. Tumor feeding vessels were superselected where possible, the catheter was inserted to the level of the segmental arteries, subsegmental arteries, or lobar branches, and a solution containing 20-60 mg of doxorubicin hydrochloride (ADM; Dong-a Pharmacy, Seoul, Korea) and 2-20 mLof iodized oil (lipiodol) was infused through the catheter (5 French) or microcatheter (2.8 or 3 French). The dosage of doxorubicin and lipiodol was determined according to the tumor size, the presence of arteriovenous shunts or extrahepatic collateral vessels, and the underlying liver functions
Study NCT03479359 — intervention group
Intervention type: BEHAVIORAL
Intervention: Routine review of DRE results by attending doctors
Description: Let the internship regularly compare DRE result and the pathology outcome of prostate biopsy of each patient.
Study NCT04075097 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: 1 session
Study NCT04075097 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Iyengar yoga
Description: 1 session
Study NCT01998997 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family educational intervention
Description: The intervention is an educational intervention directed towards delirium prevention specifically for family members of hospitalized seniors. Family members will be encouraged to perform specific interventions that may decrease incident delirium.
Study NCT01998997 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Family educational intervention
Description: The intervention is an educational intervention directed towards delirium prevention specifically for family members of hospitalized seniors. Family members will be encouraged to perform specific interventions that may decrease incident delirium.
Study NCT04037306 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Butyrate Feedback
Description: Measure concentrations of stool butyrate by gas chromatography, returned to participants in summary report.
Study NCT04037306 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fiber Feedback
Description: Estimated fiber consumption from menu records of weight loss facility.
Study NCT04072666 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attempted Suicide Short Intervention Program (ASSIP)
Description: The first session is based on a narrative interview with the consumer relating the personal story of how the point of attempting suicide was reached, videorecorded with consent. The second session involves the therapist and consumer watching the session together to reactivate the consumer's mental state during the crisis in a safe environment. Automatic thoughts, emotions, psychological pain and stress, and contingent behaviour are discussed. A psycho-educative handout is given to consumers. The third session involves discussing the handout. A credit card size leaflet is provided, with long term goals, individual warning signs and safety strategies listed, in addition to a card with crisis phone numbers. The sessions are followed by letters sent over 24 months (Michel, Valach \& Gysin-Maillart, 2017).
Study NCT04072666 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Description: The intervention incorporates skills development and emphasises internal self-management. Therapy focuses on the identification of internal, external and/or thematic triggers for suicidal thinking and behaviours, as well as factors that maintain the desire to suicide, using thought records and/or chain analyses. Therapy aims to challenge distortions and misconceptions, including core beliefs that interfere with the motivation to initiate the process of problem solving and distress tolerance, by working on acceptance of emotional and/or physical pain. The final phase of treatment focuses on relapse prevention. CBT can challenge maladaptive beliefs, improve problem solving skills and social competence.
Study NCT04072666 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Suicide Prevention Pathway (SPP)
Description: The standardised care approach involves a Suicide Prevention Pathway (SPP) modelled on the Zero Suicide Framework, utilising comprehensive chronological assessment of suicide events (CASE) (Shea, 2009) to elicit suicidal intent, the prevention orientated risk formulation (Pisani, Murrie, \& Silverman, 2016), brief interventions conducted with the consumer during their initial assessment prior to the treatment setting (Stanley et al., 2016), Safety Planning Intervention, Counselling on Access to Lethal Means (CALM), brief patient/carer information, rapid, structured follow up, safe transitions of care and caring contacts (Fleischmann et al., 2008). The SPP is supported by a blended learning course with online and face-to-face training for staff.
Study NCT04072666 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Suicide Prevention Pathway (SPP)
Description: The standardised care approach involves a Suicide Prevention Pathway (SPP) modelled on the Zero Suicide Framework, utilising comprehensive chronological assessment of suicide events (CASE) (Shea, 2009) to elicit suicidal intent, the prevention orientated risk formulation (Pisani, Murrie, \& Silverman, 2016), brief interventions conducted with the consumer during their initial assessment prior to the treatment setting (Stanley et al., 2016), Safety Planning Intervention, Counselling on Access to Lethal Means (CALM), brief patient/carer information, rapid, structured follow up, safe transitions of care and caring contacts (Fleischmann et al., 2008). The SPP is supported by a blended learning course with online and face-to-face training for staff.
Study NCT01829685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir, Adefovir
Study NCT02521025 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent feeding pattern
Description: Intermittent feeding